Prot #CRDF-004: A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date10/1/24 → 10/1/25

Funding

  • Pfizer Inc. (Prot #CRDF-004 // Prot #CRDF-004)
  • Cardiff Oncology, Inc. (Prot #CRDF-004 // Prot #CRDF-004)